Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 6;9(2):e1419. doi: 10.1097/TXD.0000000000001419

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

FIGURE 2. — Kaplan-Meier analysis of the rates of BPAR^a >24 mo in the ITT^b population. ^aCellular (Banff IA or higher) or humoral BPAR. ^bOne patient randomized to BELA+EVL was treated with TAC+MMF for the entire 2-y study period and was analyzed “as-randomized” (ie, in the BELA+EVL group) in the ITT analysis. BELA, belatacept; BPAR, biopsy-proven acute rejection; EVL, everolimus; ITT, intention-to-treat; MMF, mycophenolate mofetil; TAC, tacrolimus.